KROS · Keros Therapeutics, Inc.
AI read · Good for KROS
The AI's read
The Takeda payment adds cash, and Keros says it can cover planned costs into 2029 after the share purchases. The company may spend up to $5 million, but it does not have to.
Keros received a $20 million Takeda payment and approved spending up to $5 million on shares. That could use some cash, but Keros expects enough to cover planned costs into 2029 after the purchases.
The Takeda payment adds cash, and Keros says it can cover planned costs into 2029 after the share purchases. The company may spend up to $5 million, but it does not have to.
Follow Keros Therapeutics, Inc. (KROS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for KROS